Immunome reports Q1 net loss $129.5M; cash $309.7M extends into 2026; AL102 topline data H2 2025

Immunome Inc.

2024-Q1 EPS reported -$2.51 revenue$1,029,000

Net loss of $129.5M ($2.51 diluted EPS) includes $112.0M in IPR&D expenses from AL101/AL102 and IM-1021 acquisitions.
Cash, cash equivalents and marketable securities $309.7M as of March 31, 2024; runway expected into 2026.
R&D expense $15.4M; G&A expense $6.0M, including $1.8M stock-based compensation.
Phase 3 RINGSIDE Part B for AL102 fully enrolled; topline data expected second half 2025.
IND submissions for IM-1021 (ROR1 ADC) and IM-3050 (FAP-targeted RLT) expected Q1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immunome Inc. reported first quarter ended March 31, 2024 results: net income net loss of $129.5 million, EPS basic and diluted net loss per share attributable to common stockholders of $2.51.

Period: first quarter ended March 31, 2024
Net income: net loss of $129.5 million
EPS: basic and diluted net loss per share attributable to common stockholders of $2.51
Result: reported results

Exact text from the filing

Immunome, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunome Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-060893

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.